Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Versartis Inc (NASDAQ:VSAR)

12.25
Delayed Data
As of Sep 30
 +0.10 / +0.82%
Today’s Change
6.17
Today|||52-Week Range
14.69
-1.13%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$358.9M

Company Description

Versartis, Inc. is an endocrine-focused biopharmaceutical company. It develops long-acting therapeutic proteins for the treatment of endocrine disorders. The company develops new therapeutic proteins utilizing the novel half-life extension technology XTEN. Versartis was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Redwood City, CA.

Contact Information

Versartis, Inc.
4200 Bohannon Drive
Menlo Park California 94025
P:(650) 963-8580
Investor Relations:

Employees

Shareholders

Individual stakeholders52.70%
Mutual fund holders28.19%
Other institutional26.45%

Top Executives

Jay P. ShepardPresident, Chief Executive Officer & Director
Joshua T. BrummChief Financial Officer & Head-Investor Relations
Colin HislopChief Medical Officer
Bert BakkerSenior Vice President-Medical Affairs
Shane M. WardSenior Vice President-Legal & Compliance